Notebook

Closing the Door Softly A "Strong Move" Setting A Score AMP-lification What About Bugsy? More Media Messages Home Improvement Now that Bernadine Healy has said she will resign June 30 as director of the National Institutes of Health, at least some of her previous critics have opted to let bygones be bygones--and to sound more favorable in assessing Healy's tenure at NIH. For example, Phillip Sharp, head of the biology department at the Massachusetts Institute of Technology and a past NIH det

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

On the subject of Healy's achievements at the NIH helm, MIT's Sharp voiced particular approval on matters involving Francis S. Collins, director of the University of Michigan's Genome Technology and Genetic Diseases Center. Collins has tentatively accepted an offer to become the new head of the multibillion- dollar Human Genome Project--succeeding James Watson, whom Healy forced out. Says Sharp: "I think the development of the human genome initiative, and bringing Francis Collins there, was a strong move by her."

The federal government has admitted in court that the President's Council of Advisers on Science and Technology (PCAST) improperly closed meetings to the press and public in violation of the Federal Advisory Committee Act (FACA). In an agreement filed last month in United States District Court for the District of Columbia, to settle a lawsuit brought by science journalists (Barton Reppert, The Scientist, July 6, 1992, page 1), the government, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies